BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... and Non-surgical Conditions” will be presented in a poster session on Saturday, October 19, from 10:00-11:30 a.m ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.26% of ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Jessica Fye has given her Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ promising developments, particularly concerning their drug suzetrigine. The recent ...

Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$855 Current share price of US$483 suggests Vertex Pharmaceuticals is potentially 44% undervalued ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) and keeping the price target at $473.00. Terence Flynn has given his Hold ...

Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$855 Current share price of US$483 suggests Vertex Pharmaceuticals is potentially 44% undervalued Analyst ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $128.7 billion by market cap ...